drugset / Trial / NCT05480098

Brimonidine for Intraoperative Hemostasis

NCT05480098

Phase 4 Withdrawn University of Louisville
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to observe and report the effects of topical ophthalmic brimonidine in oculofacial plastic surgery.

Timeline

Start
2022-05-26
Primary completion
2024-05-22
Completion
2024-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.15 % Topical
Subject Brimonidine Small molecule 0.2 % Topical

Indications